Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshiaki Okamoto is active.

Publication


Featured researches published by Toshiaki Okamoto.


Nephrology | 2016

Renal shear wave velocity by acoustic radiation force impulse did not reflect advanced renal impairment.

Tomoaki Takata; Masahiko Koda; Takaaki Sugihara; Shinobu Sugihara; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Keiko Hosho; Yukari Mae; Takuji Iyama; Takeaki Fukui; Satoko Fukuda; Chishio Munemura; Hajime Isomoto

Acoustic radiation force impulse is a noninvasive method for evaluating tissue elasticity on ultrasound. Renal shear wave velocity measured by this technique has not been fully investigated in patients with renal disease. The aim of the present study was to compare renal shear wave velocity in end‐stage renal disease patients and that in patients without chronic kidney disease and to investigate influencing factors.


Molecular Medicine Reports | 2015

Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice

Takumi Onoyama; Masahiko Koda; Toshiaki Okamoto; Manabu Kishina; Tomomitsu Matono; Takaaki Sugihara; Yoshikazu Murawaki

Non-alcoholic steatohepatitis is characterized by hepatic fat accumulation, inflammation and varying degrees of fibrosis. The dipeptidyl peptidase‑IV enzyme is important in glucose metabolism, as well as lipid accumulation, extracellular matrix metabolism and immune stimulation. Furthermore, the enzyme activity of dipeptidyl peptidase‑IV is known to be increased in non‑alcoholic steatohepatitis. Therefore, dipeptidyl peptidase‑IV inhibitors are potential therapeutic agents for non‑alcoholic steatohepatitis. The present study assessed the therapeutic effects of sitagliptin, a dipeptidyl peptidase‑IV inhibitor, on non‑alcoholic steatohepatitis using fatty liver Shionogi‑ob/ob male mice. Sitagliptin (2 mg/kg/day; n=10) or placebo (control; n=10) was orally administered to fatty liver Shionogi‑ob/ob mice for 12 weeks, and hepatic steatosis, fibrosis, inflammation and oxidative stress were assessed in comparison with the controls. Sitagliptin administration reduced body weight and blood glucose levels, and improved hepatic fibrosis. It also inhibited the gene expression levels of fatty acid synthase, transforming growth factor‑β1, tissue inhibitor of metalloproteinases‑1, procollagen‑type 1, tumor necrosis factor‑α, monocyte chemoattractant protein‑1 and enhanced peroxisome proliferator activated receptor‑α. Furthermore, a marked attenuation of hepatic stellate cell activation and Kupffer cells was observed in the sitagliptin group. A decrease in oxidative stress and apoptosis was also observed. Sitagliptin attenuated the progression of hepatic fibrosis by improving lipid metabolism, inflammation and oxidative stress in non-alcoholic steatohepatitis.


Journal of Hepatology | 2015

Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma

Masahiko Koda; Shiho Tokunaga; Toshiaki Okamoto; Masanori Hodozuka; Kennichi Miyoshi; Manabu Kishina; Yuki Fujise; Jun Kato; Tomomitsu Matono; Takaaki Sugihara; Kenji Oyama; Keiko Hosho; Jun-ichi Okano; Yoshikazu Murawaki; Suguru Kakite; Eijiro Yamashita

BACKGROUND & AIMS The aim of this study was to investigate the feasibility of ablative margin (AM) grading by magnetic resonance imaging (MRI) with Gd-EOB-DTPA administered prior to radiofrequency ablation (RFA), and to identify factors for achieving a sufficient AM and predictors for local tumor progression. METHODS A total of 124 hepatocellular carcinomas (HCCs) were treated by RFA after Gd-EOB-DTPA administration. MRI and enhanced CT were performed within seven hours and one month after RFA. The AM assessment was categorized using three grades: AM (+), low-intensity area with continuous high-intensity rim; AM zero, low-intensity area with discontinuous high-intensity rim; and AM (-), low-intensity area extends beyond the high-intensity rim. Patients were followed and local tumor progression was observed. RESULTS AM (+), AM zero, AM (-), and indeterminate were found in 34, 33, 26, and 31 nodules, respectively. The overall agreement rate between MRI and enhanced CT for the diagnosis of AM was 56.8%. The κ coefficient was 0.326 (p<0.001), indicating moderate agreement. Multivariate logistic regression analysis showed that a significant factor for the achievement of AM (+) on MRI was no contiguous vessels. The cumulative local tumor progression rates (0% at 1, 2, and 3 years) in 33 AM (+) nodules were significantly lower than those (3.6%, 11.5%, and 18.3% at 1, 2, and 3 years respectively) in 32 AM zero nodules. A multivariate Cox proportional hazards model identified tumor size as an independent predictor for local tumor progression. CONCLUSION Gd-EOB-DTPA-MRI enabled an early assessment of RFA effectiveness in the majority ofHCC nodules. Local tumor progression was not detected in AM (+) nodules during the follow-up.


World Journal of Hepatology | 2016

Antifibrotic effects of ambrisentan,an endothelin-A receptor antagonist,in a non-alcoholic steatohepatitis mouse model

Toshiaki Okamoto; Masahiko Koda; Kennichi Miyoshi; Takumi Onoyama; Manabu Kishina; Tomomitsu Matono; Takaaki Sugihara; Keiko Hosho; Jun-ichi Okano; Hajime Isomoto; Yoshikazu Murawaki

AIM To examine the effects of the endothelin type A receptor antagonist ambrisentan on hepatic steatosis and fibrosis in a steatohepatitis mouse model. METHODS Fatty liver shionogi (FLS) FLS-ob/ob mice (male, 12 wk old) received ambrisentan (2.5 mg/kg orally per day; n = 8) or water as a control (n = 5) for 4 wk. Factors were compared between the two groups, including steatosis, fibrosis, inflammation, and endothelin-related gene expression in the liver. RESULTS In the ambrisentan group, hepatic hydroxyproline content was significantly lower than in the control group (18.0 μg/g ± 6.1 μg/g vs 33.9 μg/g ± 13.5 μg/g liver, respectively, P = 0.014). Hepatic fibrosis estimated by Sirius red staining and areas positive for α-smooth muscle actin, indicative of activated hepatic stellate cells, were also significantly lower in the ambrisentan group (0.46% ± 0.18% vs 1.11% ± 0.28%, respectively, P = 0.0003; and 0.12% ± 0.08% vs 0.25% ± 0.11%, respectively, P = 0.047). Moreover, hepatic RNA expression levels of procollagen-1 and tissue inhibitor of metalloproteinase-1 (TIMP-1) were significantly lower by 60% and 45%, respectively, in the ambrisentan group. Inflammation, steatosis, and endothelin-related mRNA expression in the liver were not significantly different between the groups. CONCLUSION Ambrisentan attenuated the progression of hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing procollagen-1 and TIMP-1 gene expression. Ambrisentan did not affect inflammation or steatosis.


Hepatology Research | 2018

Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: WFA+-M2BP predicts HCC in NAFLD

Miwa Kawanaka; Yasuyuki Tomiyama; Hideyuki Hyogo; Masahiko Koda; Toshihide Shima; Hiroshi Tobita; Akira Hiramatsu; Ken Nishino; Toshiaki Okamoto; Shuichi Sato; Yuichi Hara; Sohji Nishina; Hirofumi Kawamoto; Kazuaki Chayama; Takeshi Okanoue; Keisuke Hino

As it is not practical to perform regular screening for hepatocellular carcinoma (HCC) in all patients with non‐alcoholic fatty liver disease (NAFLD), there is a need to identify NAFLD patients who are at high risk for HCC. Wisteria floribunda agglutinin‐positive Mac‐2 binding protein (WFA+‐M2BP) has been shown to be a surrogate marker for predicting HCC as well as a liver fibrosis marker in patients with chronic hepatitis B and C. The aim of this study was to investigate whether WFA+‐M2BP predicts HCC development in NAFLD patients.


Clinical Imaging | 2017

Utility of virtual touch quantification in the diagnosis of pancreatic ductal adenocarcinoma

Takumi Onoyama; Masahiko Koda; Yuki Fujise; Tomoaki Takata; Soichiro Kawata; Toshiaki Okamoto; Kennichi Miyoshi; Tomomitsu Matono; Takaaki Sugihara; Kazuya Matsumoto; Koichiro Kawaguchi; Kenichi Harada; Kazuo Yashima; Hajime Isomoto

This study aimed to compare the tissue stiffness of pancreatic ductal adenocarcinoma (PDAC) with that of pancreatic parenchyma using virtual touch quantification (VTQ). SWV was measured in 34 PDAC lesions and in pancreatic parenchyma of both controls and patients. SWVs in PDAC lesions were significantly higher than in pancreatic parenchyma in both healthy controls and in patients with PDAC. The area under the ROC for diagnosis of PDAC was 0.94 for pancreatic parenchyma in healthy controls, and 0.85 for pancreatic parenchyma in patients with PDAC. VTQ can provide a useful and additional information for diagnosis of PDAC.


Nephron | 2016

Left Renal Cortical Thickness Measured by Ultrasound Can Predict Early Progression of Chronic Kidney Disease

Tomoaki Takata; Masahiko Koda; Takaaki Sugihara; Shinobu Sugihara; Toshiaki Okamoto; Kenichi Miyoshi; Masanori Hodotsuka; Yuki Fujise; Tomomitsu Matono; Jun-ichi Okano; Keiko Hosho; Takuji Iyama; Takeaki Fukui; Satoko Fukuda; Chishio Munemura; Hajime Isomoto

Aims: The kidney becomes atrophic in advanced chronic kidney disease, and renal size and parenchymal volume correlate with renal function. However, alterations in renal parenchymal volume have not been adequately studied in terms of the renal cortex and medulla. We investigated the relationship between the changes in the renal cortex and medulla and renal function. Methods: Renal ultrasound (US) parameters including renal length, parenchymal thickness, cortical thickness and medullary thickness were assessed in 176 subjects, who were categorized into 4 groups based on the estimated glomerular filtration rate (ml/min/1.73 m2): group 1, ≥90; group 2, ≥60 but <90; group 3, ≥30 but <60; and group 4, <30. Renal US parameters in both kidneys were compared among the 4 groups. Results: We found stepwise associations in renal length, cortical thickness and parenchymal thickness with decreased renal function. Medullary thickness showed no changes among groups 1-3. Multiple linear regression analysis including sex, age and renal US parameters showed that only renal length was an independent predictor of renal function. When analyzed in groups 1-3, cortical thickness was the strongest associated parameter. Lower cortical left/right ratio (left cortical thickness/right cortical thickness) showed a stepwise association with a decrease in renal function. Conclusion: Renal length and cortical thickness measured by US were correlated with renal function. In particular, left cortical thickness could help to detect early changes in renal function.


PLOS ONE | 2016

A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model

Kinya Okamoto; Masahiko Koda; Toshiaki Okamoto; Takumi Onoyama; Kenichi Miyoshi; Manabu Kishina; Jun Kato; Shiho Tokunaga; Takaaki Sugihara; Yuichi Hara; Keisuke Hino; Yoshikazu Murawaki


Journal of Medical Ultrasonics | 2018

Two patterns of contrast-enhanced ultrasonography with Sonazoid® in spontaneous rupture of hepatocellular carcinoma: a report of four cases

Takaaki Sugihara; Masahiko Koda; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Hajime Isomoto


Kanzo | 2018

Liver stiffness is a useful marker for assessing the therapeutic effect of angioplasty in Budd-Chiari syndrome: A case report

Ran Nagahara; Tomomitsu Matono; Masahiko Koda; Yukako Matsuki; Masashi Yamane; Toshiaki Okamoto; Kenichi Miyoshi; Takakazu Nagahara; Takaaki Sugihara; Kenji Ohyama; Jun-ichi Okano; Hajime Isomoto; Mika Kodani; Shinsaku Yata; Yasufumi Ohuchi

Collaboration


Dive into the Toshiaki Okamoto's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge